News

Omidubicel showed encouraging clinical benefit in a phase 3 study vs standard myeloablative umbilical cord blood in patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant. Now, the FDA has approved the agent for this indication.

In a presentation given during the 2023 National Comprehensive Cancer Network Annual Conference, Mitesh J. Borad, MD, discussed treatment options for advanced hepatocellular carcinoma.

Edwin Choy, MD, discusses adjuvant treatments for patients with gastrointestinal stromal tumors.

Positive data from the phase 3 KarMMA-3 study has led to multiple regulatory applications being accepted for ide-cel as a treatment option for patients with relapsed/refractory multiple myeloma.

Eytan M. Stein, MD, provides community oncologists with an overview of the unmet needs in the acute myeloid leukemia space and provides recommendations for those treating patients with this disease.

During a live, virtual event, Thomas Hutson, DO, PharmD, discussed the case of a 54-year-old man with a history of metastatic renal cell carcinoma.

Using the recommended doses of 50 and 70 mg per day from a phase 1a trial of NXP800, the agent will be further evaluated in patients with platinum-resistant, ARID1a-mutated ovarian cancer.

The FDA has requested positive results from a second clinical study of SGX301 in patients with early stage cutaneous T-cell lymphoma before filing a new drug application.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Wesley Burkett, MD, discusses some novel targets that are available and being evaluated in the endometrial cancer space.

The FDA has now granted OM-301 2 orphan drug designations for the treatment of patients with multiple myeloma and acute myeloid leukemia.

Carolyn Owen, MD, discusses emerging and exciting data in the chronic lymphocytic leukemia space.

The effects of chemotherapy-induced myelosuppression for extensive-stage small cell lung cancer were assessed in a new study which used a real-world community oncology setting.

The phase 3 MAJIC study is underway to compare 2 frontline regimens for patients with chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Ajay Nooka, MD, discussed findings from the phase 3 KarMMa-3 trial and the use of ide-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Results from the EARLY-MYO-BC trial assessing the pyrotinib’s cardiac impacts may help researchers select an appropriate anti-HER2 treatment when managing patients with HER2-positive breast cancer.

KEYNOTE-859 findings are under review by the FDA as the regulatory body considers an approval application for pembrolizumab plus chemotherapy for the treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Mirvetuximab soravtansine is being assessed in combination with bevacizumab as a treatment for patients with folate receptor-alpha-positive recurrent platinum-sensitive ovarian cancer.

Roby Thomas, MD, provides ideas for oncologists to consider while multiple chemotherapy drug are on shortage in the United States.

Multiple cases of unacceptable toxicity requiring dose reductions have occurred in a phase 1 study of MT-0169 in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The FDA has placed a partial clinical hold on the study

Topline data from part A of the THIO-101 trial showed that patients treated with THIO plus cemiplimab had mild toxicities, including grade 1 fatigue and muscle pain, and 1 case of grade 3 nausea among patients with non–small cell lung cancer.

A phase 2, open-label clinical trial is evaluating treatment with QBS72S in patients with histologically-confirmed breast cancer that has developed brain metastases after a prior cytotoxic chemotherapy regimen.

In a study performed at MD Anderson Cancer Center, there was no significant overall survival impact in patients with anaplastic thyroid cancer who had prior differentiated thyroid cancer, concomitant differentiated thyroid cancer, and prior non thyroid cancers.

Rebecca Silbermann, MD, MMS, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study and the importance of individualizing treatment for patients with multiple myeloma.

TP-1287, an investigational oral phosphate prodrug of the CDK9 inhibitor alvocidib, has been granted an orphan drug designation by the FDA for patients with Ewing sarcoma.

CB-011 has received a fast track designation from the FDA for the treatment of relapsed/refractory multiple myeloma and is being investigated in the ongoing CaMMouflage study.

The phase 3 Karmma-3 trial of ide-cel in patients with triple-class-exposed relapsed/refractory multiple myeloma generated significantly improved progression-free survival and overall response rates vs standard regimens.

A new apalutamide tablet has become available for oncologists in the United States who treat non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

Gayathri Ravi, MD, discusses the role minimal residual disease plays in decision making and treating patients with hematologic malignancies.

Mixed study results for ibrutinib have led the developer to voluntarily withdraw the agent from the United States market for the treatment of mantle cell and marginal zone lymphoma subgroups.